Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)

Inclusion criteria : * Male or female, more than 18 and less than 65 years of age, * Women using a method of contraception and with a negative pregnancy test before entering the study, or women who have been menopausal for at least 1 year, * Patients meeting one of the following criteria: * Closed benign trauma of the motor system occurring within the last 24 hours, * Contusion of the motor system occurring within the last 24 hours, * Acute rheumatologic conditions (acute lower back pain, lumbar sciatica, cervicobrachial neuralgia), * Abarticular rheumatism, * Requiring treatment with Bi-Profenid for 5 days, * With resting pain intensity measured on a numeric scale at baseline \>or= 3 (before administration of any treatment), * Receiving a prior medical examination suited to the study Exclusion criteria : * Need for surgery, * Need for hospitalization, * Need for an analgesic other than step I at the baseline visit, * Need for treatment with another selective or non-selective NSAID (per os and/or topical), including aspirin, selective cyclo-oxygenase 2 inhibitors, corticosteroids or muscle relaxants at baseline and throughout the study, * Serious trauma: knee luxation, any fracture, ruptures such as Achilles tendon rupture, * Sprain treated with a cast, * Bursitis, * Local and/or general severe infection, * Pregnant or nursing women, * Hypersensitivity to ketoprofen or to any of the excipients of the product, * Previous history of asthma triggered by taking ketoprofen or substances with similar activity such as other NSAIDs or aspirin, * Gastrointestinal haemorrhage, cerebrovascular haemorrhage or other active haemorrhage, * Previous history of digestive haemorrhage or perforation during previous NSAID treatment, * Active intestinal ulcer, * Active peptic ulcer, previous history of peptic ulcer or recurrent haemorrhage (2 separate episodes or more of haemorrhage or ulcerations detected), * Severe hepatic failure, * Severe renal failure, * Severe heart failure, * Uncontrolled hypertension, * Hypersensitivity or intolerance to gluten, due to the presence of wheat starch (gluten), * Patients treated with oral anticoagulants, heparins, platelet antiaggregants, selective serotonin reuptake inhibitors (SSRI), lithium, methotrexate, pemetrexed and immunosuppressants The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.